All In Biotech

Drug Trial Radar · NCT01329029

Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Combinations of Long-acting β2-agonists (LABA) and Inhaled Glucocorticosteroid (ICS)

Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial

Last checked: Nov 19, 2026Latest source record: Dec 13, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,945 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,945

Actual

Start

May 2011

Primary completion

Mar 2014

Study completion May 2014

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Apr 5, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects. Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.

Conditions

  • Chronic Obstructive Pulmonary Disease

Interventions

  • RoflumilastDrug

    500 µg, once daily

  • PlaceboDrug

    once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Moderate or Severe COPD Exacerbations Per Patient Per YearTime frame: 52 weeks

Locations

180 sites in 21 countries. Site status is shown where the registry gives one.

  • Nycomed Investigational Site

    Box Hill, Australia

  • Nycomed Investigational Site

    Clayton, Australia

  • Nycomed Investigational Site

    Concord, Australia

  • Nycomed Investigational site

    Daws Park, Australia

  • Nycomed Investigational Site

    Frankston, Australia

  • Nycomed Investigational Site

    Heidelberg, Australia

  • Nycomed Investigational Site

    Parkville, Australia

  • Nycomed Investigational Site

    Toorak Gardens, Australia

  • Nycomed Investigational Site

    Feldbach, Austria

  • Nycomed Investigational Site

    Graz, Austria

  • Nycomed Investigational Site

    Salzburg, Austria

  • Nycomed Investigational Site

    Vienna, Austria

  • Nycomed Investigational Site

    Brussels, Belgium

  • Nycomed Investigational Site

    Brussels, Belgium

  • Nycomed Investigational Site

    Halen, Belgium

  • Nycomed Investigational Site

    Liège, Belgium

  • Nycomed Investigational Site

    Malmedy, Belgium

  • Nycomed Investigational Site

    Belo Horizonte, Brazil

  • Nycomed Investigational Site

    Botucatu, Brazil

  • Nycomed Investigational Site

    Florianópolis, Brazil

  • Nycomed Investigational Site

    Goiânia, Brazil

  • Nycomed Investigational Site

    Porto Alegre, Brazil

  • Nycomed Investigational Site

    Rio de Janeiro, Brazil

  • Nycomed Investigational Site

    São Paulo, Brazil

  • Nycomed Investigational Site

    Vitória, Brazil

  • Nycomed Investigational Site

    Hamilton, Canada

  • Nycomed Investigational Site

    Kingston, Canada

  • Nycomed Investigational Site

    Lachine, Canada

  • Nycomed Investigational Site

    Niagara Falls, Canada

  • Nycomed Investigational Site

    Richmond Hill, Canada

  • Nycomed Investigational Site

    Toronto, Canada

  • Nycomed Investigational Site

    Toronto, Canada

  • Nycomed Investigational Site

    Winnepeg, Canada

  • Nycomed Investigational Site

    Hellerup, Denmark

  • Nycomed Investigational Site

    Hillerød, Denmark

  • Nycomed Investigational Site

    Hvidovre, Denmark

  • Nycomed Investigational Site

    København NV, Denmark

  • Nycomed Investigational Site

    Férolles-Attilly, France

  • Nycomed Investigational Site

    Nîmes, France

  • Nycomed Investigational Site

    Poitiers, France

Showing 40 of 180 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.